Bravecto® Spot-On solution for cats
Bravecto Spot-On Solution is an ectoparasiticide treatment for cats that contains the active ingredient fluralaner. It is a flea and tick treatment of the isoxazoline class for cats with a duration of effect of 12 weeks.
Bravecto contributes towards the control of the environmental flea populations due to the rapid onset of action and long lasting efficacy against adult fleas on the animal and the absence of viable egg production.
Information on ordering Bravecto is available after login.
Presentation
Bravecto is a clear colourless to yellow spot-on formulation.
Active ingredients
Each ml contains 280 mg fluralaner.
Target species
Cats
Indications for use:
This veterinary medicinal product is a systemic insecticide and acaricide that provides:
- Immediate and persistent flea (Ctenocephalides felis) and tick (Ixodes ricinus) killing activity for 12 weeks.
- Used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
- Treatment of infestations with ear mites (Otodectes cynotis).
Bravecto Spot-on for cats can be used from 9 weeks of age and 1.2 kg in bodyweight.
Packaging
Each box contains 1 pipette made of laminated aluminium/polyproplene foil closed with an HDPE cap and packed in laminated aluminium foil sachet.
Legal Category
POM-V
Frequently Asked Questions
-
Does Bravecto® have any breed specific contraindications?
There are no breed contraindications for this product. Any contraindications are listed in the product datasheet under summary of product characteristics.
-
Swapping to Bravecto® from another flea treatment
There are no known incompatibilities with other classes of ectoparasiticides or parasiticide. It would be a reasonable precaution to observe a normal retreatment interval after the use of another product in the isoxazoline class and in the case of other products to not apply two products simultaneously so it was clear which product use was responsible in the unlikely occurrence of an adverse event.
-
Bravecto® and Environmental impact
MSD Animal Health conducts environmental risk assessments on its products from the development phase through product launch to understand and manage product impacts from manufacturing and patient use. Our environmental risk assessments are conducted in accordance with applicable stringent global regulations, including the regulatory review processes of the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Product environmental safety profiles are reassessed during periodic renewals of product filings and risk mitigation actions are implemented when needed.
The potential transfer of active ingredients used in our spot-on and chew products from the dog into surface water has been assessed in the European environmental risk assessments. Based on their intrinsic properties we are confident in the absence of transfer into surface water for the active ingredients in the registered products in our companion animal line. However, please be aware of the statement on the Summary of Product Characteristics that dogs treated with Bravecto Spot-On should not be allowed to be immersed in water or swim in water courses within 3 days after treatment. There is no specifically identified risk to fish or aquatic species from this activity.
Following oral treatment of dogs fluralaner will mainly be excreted via the faeces, thus exposure of bees to fluralaner is considered very unlikely. Overall, there were no environmental concerns identified in the regulatory submissions or reviews. The environmental exposure through the oral treatment of dogs is considered too low to impact the environment.
-
What are the excipients in Bravecto® Spot on solution for Dogs and Cats?
The excipients in the Bravecto Spot on solution for Dogs and Cats are dimethylacetamide, glycofurol, acetone.
-
What is the last day that Bravecto® can be given?
The expiry date of the product is stated on the packaging and refers to the last day of that month. Do not use the product after the expiry date.
Further information is available from the SPC, datasheet or package leaflet.
Advice should be sought from the medicine prescriber.
Prescription decisions are for the person issuing the prescription alone.
Use Medicines Responsibly.
Product images are representations of packaging and may not accurately reflect the current packaging available in the GB marketplace.
Date of preparation: January 2026
References
*Bravecto Spot-on has 12-week duration of efficacy against flea and tick species indicated in the SPC. Bravecto Chewable Tablets include an 8-week immediate and persistent killing activity against Rhipicephalus sanguineus. For further information refer to the relevant SPC.